199 related articles for article (PubMed ID: 19430202)
1. Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN 0.5 ml in adults aged 18-67 years.
Loew-Baselli A; Poellabauer EM; Pavlova BG; Fritsch S; Koska M; Bobrovsky R; Konior R; Ehrlich HJ
Hum Vaccin; 2009 Aug; 5(8):551-6. PubMed ID: 19430202
[TBL] [Abstract][Full Text] [Related]
2. Seropersistence of TBE virus antibodies 10 years after first booster vaccination and response to a second booster vaccination with FSME-IMMUN 0.5mL in adults.
Konior R; Brzostek J; Poellabauer EM; Jiang Q; Harper L; Erber W
Vaccine; 2017 Jun; 35(28):3607-3613. PubMed ID: 28545923
[TBL] [Abstract][Full Text] [Related]
3. Five year follow-up after primary vaccination against tick-borne encephalitis in children.
Wittermann C; Izu A; Petri E; Gniel D; Fragapane E
Vaccine; 2015 Apr; 33(15):1824-9. PubMed ID: 25728316
[TBL] [Abstract][Full Text] [Related]
4. Antibody response following administration of two paediatric tick-borne encephalitis vaccines using two different vaccination schedules.
Wittermann C; Schöndorf I; Gniel D
Vaccine; 2009 Mar; 27(10):1661-6. PubMed ID: 18940221
[TBL] [Abstract][Full Text] [Related]
5. Seropersistence and booster response following vaccination with FSME-IMMUN in children, adolescents, and young adults.
Poellabauer E; Angermayr R; Behre U; Zhang P; Harper L; Schmitt HJ; Erber W
Vaccine; 2019 May; 37(24):3241-3250. PubMed ID: 30928173
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies.
Loew-Baselli A; Konior R; Pavlova BG; Fritsch S; Poellabauer E; Maritsch F; Harmacek P; Krammer M; Barrett PN; Ehrlich HJ;
Vaccine; 2006 Jun; 24(24):5256-63. PubMed ID: 16624457
[TBL] [Abstract][Full Text] [Related]
7. Can the booster interval for the tick-borne encephalitis (TBE) vaccine 'FSME-IMMUN' be prolonged? - A systematic review.
Steffen R; Erber W; Schmitt HJ
Ticks Tick Borne Dis; 2021 Sep; 12(5):101779. PubMed ID: 34298356
[TBL] [Abstract][Full Text] [Related]
8. Antibody persistence after two vaccinations with either FSME-IMMUN® Junior or ENCEPUR® Children followed by third vaccination with FSME-IMMUN® Junior.
Prymula R; Pöllabauer EM; Pavlova BG; Löw-Baselli A; Fritsch S; Angermayr R; Geisberger A; Barrett PN; Ehrlich HJ
Hum Vaccin Immunother; 2012 Jun; 8(6):736-42. PubMed ID: 22699436
[TBL] [Abstract][Full Text] [Related]
9. Serological response to tick-borne encephalitis (TBE) vaccination in the elderly--results from an observational study.
Jílková E; Vejvalková P; Stiborová I; Skorkovský J; Král V
Expert Opin Biol Ther; 2009 Jul; 9(7):797-803. PubMed ID: 19527104
[TBL] [Abstract][Full Text] [Related]
10. Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity.
Ehrlich HJ; Pavlova BG; Fritsch S; Poellabauer EM; Loew-Baselli A; Obermann-Slupetzky O; Maritsch F; Cil I; Dorner F; Barrett PN
Vaccine; 2003 Dec; 22(2):217-23. PubMed ID: 14615149
[TBL] [Abstract][Full Text] [Related]
11. Long-term persistence of tick-borne encephalitis antibodies in children 5 years after first booster vaccination with Encepur Children.
Wittermann C; Petri E; Zent O
Vaccine; 2009 Mar; 27(10):1585-8. PubMed ID: 19162115
[TBL] [Abstract][Full Text] [Related]
12. Long-term immunity after vaccination against tick-borne encephalitis with Encepur using the rapid vaccination schedule.
Beran J; Douda P; Gniel D; Zent O
Int J Med Microbiol; 2004 Apr; 293 Suppl 37():130-3. PubMed ID: 15146994
[TBL] [Abstract][Full Text] [Related]
13. Comparison of immunogenicity and safety between two paediatric TBE vaccines.
Pöllabauer EM; Pavlova BG; Löw-Baselli A; Fritsch S; Prymula R; Angermayr R; Draxler W; Firth C; Bosman J; Valenta B; Harmacek P; Maritsch F; Barrett PN; Ehrlich HJ
Vaccine; 2010 Jun; 28(29):4680-5. PubMed ID: 20433803
[TBL] [Abstract][Full Text] [Related]
14. Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults.
Plentz A; Jilg W; Schwarz TF; Kuhr HB; Zent O
Vaccine; 2009 Feb; 27(6):853-6. PubMed ID: 19071180
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: systematic review and meta-analysis.
Domnich A; Panatto D; Arbuzova EK; Signori A; Avio U; Gasparini R; Amicizia D
Hum Vaccin Immunother; 2014; 10(10):2819-33. PubMed ID: 25483679
[TBL] [Abstract][Full Text] [Related]
16. Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence.
Beran J; Lattanzi M; Xie F; Moraschini L; Galgani I
Vaccine; 2019 Jul; 37(32):4623-4629. PubMed ID: 29397225
[TBL] [Abstract][Full Text] [Related]
17. TBE booster immunization in adults--first experience with a new tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer.
Zent O; Schwarz TF; Plentz A; Banzhoff A; Jilg W
Int J Med Microbiol; 2004 Apr; 293 Suppl 37():134-8. PubMed ID: 15146995
[TBL] [Abstract][Full Text] [Related]
18. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up.
Rendi-Wagner P; Paulke-Korinek M; Kundi M; Wiedermann U; Laaber B; Kollaritsch H
Vaccine; 2007 Jun; 25(27):5097-101. PubMed ID: 17555850
[TBL] [Abstract][Full Text] [Related]
19. Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme.
Loew-Baselli A; Poellabauer EM; Pavlova BG; Fritsch S; Firth C; Petermann R; Barrett PN; Ehrlich HJ
Vaccine; 2011 Oct; 29(43):7307-19. PubMed ID: 21843576
[TBL] [Abstract][Full Text] [Related]
20. Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety.
Beran J; Xie F; Zent O
Vaccine; 2014 Jul; 32(34):4275-80. PubMed ID: 24950352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
